Summary of Guardant Health Q2 2026 Earnings Call

1Key Financial Results and Metrics

Total Revenue: $335 million, up 44% year-over-year.

Oncology Revenue: $219 million, a 38% increase; test volumes rose 63% to approximately 104,000 tests.

Biopharma & Data Revenue: $61 million, up 9% year-over-year, marking a record quarter.

Screening Revenue: $53 million, significantly up from $15 million in Q2 2025, driven by approximately 66,000 Shield tests.

Non-GAAP Gross Margin: 67%, slightly up from 66% a year ago.

Adjusted EBITDA Loss: $56 million, compared to a loss of $52 million in Q2 2025.

Cash and Investments: Approximately $1.2 billion; free cash flow burn was $70 million.

2Strategic Updates and Business Highlights

FDA Approvals: Received FDA approval for Guardant360 Liquid CDx and a higher-throughput, lower-COGS Shield workflow.

Market Positioning: Guardant360 Liquid CDx is the only FDA-approved liquid biopsy test integrating genomic and epigenomic content.

Growth in Oncology: Strong performance across all products, particularly Reveal, which saw over 100% volume growth.

Shield Developments: Inclusion in the American Cancer Society's colorectal cancer screening guidelines and coverage by UnitedHealth Group for adults aged 45 and older.

Data Asset Expansion: Over 1.3 million patient tests and 700,000 epigenetic profiles collected, enhancing InfinityAI capabilities.

3Forward Guidance and Outlook

Revenue Guidance for 2026: Raised to $1.34 billion to $1.36 billion, reflecting 36% to 38% growth.

Oncology Growth Expectations: Anticipated revenue growth of approximately 30% and volume growth of about 50%.

Screening Revenue Guidance: Increased to $218 million to $230 million, expecting 270,000 to 285,000 Shield tests.

Operating Expenses: Expected to be $1.08 billion to $1.1 billion, a 20% to 22% increase compared to 2025.

Cash Flow Burn: Projected to be $195 million to $205 million for the year, with a commitment to achieving cash flow breakeven by the end of 2027.

4Challenges and Points of Concern

Increased Operating Expenses: Non-GAAP operating expenses rose 34%, primarily due to commercial investments, which could pressure margins.

Cash Flow Burn: Despite improvements, the ongoing cash burn remains a concern as investments in screening and lab capacity continue.

Market Competition: The competitive landscape in liquid biopsy and multi-cancer detection remains intense, necessitating continuous innovation and market presence.

5Notable Q&A Insights

Impact of UnitedHealth Coverage: The unexpected early coverage by UnitedHealth could lead to increased volume but pricing negotiations remain uncertain.

Therapy Monitoring Growth: Significant potential in therapy monitoring with Reveal, which could become a major revenue driver once reimbursement is secured.

Guardant360 Tissue Test: Growth attributed to its unique capabilities and concurrent testing trends, with expectations for continued market share gains.

ADLT Pricing Expectations: Anticipated increase in ASP following ADLT designation, with a focus on balancing reinvestment in innovation and achieving profitability. Overall, Guardant Health reported strong growth across its business segments, driven by strategic FDA approvals and market expansions, while also navigating challenges related to operating expenses and competitive pressures. The outlook remains positive with raised revenue guidance and a clear focus on achieving cash flow breakeven by 2027.